Continuation phase fluoxetine — Competitive Intelligence Brief

Continuation phase fluoxetine (Continuation phase fluoxetine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Mental Health.

phase 3 Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule

Target snapshot

Continuation phase fluoxetine (Continuation phase fluoxetine) — University of Texas Southwestern Medical Center. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continuation phase fluoxetine TARGET	Continuation phase fluoxetine	University of Texas Southwestern Medical Center	phase 3	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Open Label (OL) Paroxetine	Open Label (OL) Paroxetine	VA Office of Research and Development	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Zoloft (antidepressant)	Zoloft (antidepressant)	Unity Health Toronto	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
citalopram (celexa)	citalopram (celexa)	Sunnybrook Health Sciences Centre	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Fluoxetine (prozac)	Fluoxetine (prozac)	Neuropharm	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class